Contact Us at Sunridge Medical

Cutting-Edge Treatment Options. Call Today! 1.800.923.7878

Contact Us
Call Today! 1.800.923-7878
Sunridge Medical
"
Cancer Metabolism Research · Investigational Therapy

DCA and Cancer: Research, Potential Benefits and Safety

Dichloroacetate (DCA) is an investigational small molecule that changes how cells process energy by inhibiting pyruvate dehydrogenase kinase. Its cancer rationale is scientifically interesting, and early human studies have established feasible dosing—but DCA is not an FDA-approved cancer treatment and has not been proven to improve survival.

At Sunridge Medical, questions about DCA are approached with measured optimism: review the cancer biology, distinguish laboratory findings from clinical outcomes, assess neuropathy risk and coordinate any investigational strategy with the patient’s oncology plan.

Mechanism explainedHuman studies summarizedNeuropathy monitoring emphasized
Request an Integrative Review →Call 1-800-923-7878
Scientific visualization of DCA research shifting cancer cell energy metabolism toward active mitochondria
DCA inhibits pyruvate dehydrogenase kinase, a metabolic target studied in laboratory models and early-phase cancer trials.
“
DCA physician review

Discuss DCA With a Team That Takes Safety Seriously

Dichloroacetate remains an investigational cancer approach and requires careful discussion of neurologic, liver and medication risks. We can review your diagnosis, prior treatment, laboratory information and questions before a physician consultation.

  • Investigational status and realistic expectations are discussed
  • Neurologic, liver and medication risks are reviewed
  • Call now for an immediate response from our Patient Care Team
Call 1-800-923-7878 →
DCA physician review

Speak With Our Patient Care Team

Share your diagnosis, treatment history and questions about DCA. We will explain what information is useful for a careful review.

* Required fields
Prefer to speak with someone now?
1-800-923-7878
  • Investigational status and realistic expectations are discussed
  • Neurologic, liver and medication risks are reviewed
  • Questions before scheduling are always welcome
DCA · Key Points

What the Evidence Can—and Cannot—Tell Us

Mechanism

DCA targets cancer metabolism

By inhibiting PDK, DCA can activate pyruvate dehydrogenase and shift cellular energy processing toward mitochondrial oxidation.

Clinical Evidence

Human studies remain early

Small phase I studies evaluated safety and dosing. They were not designed or powered to prove improved survival.

Outcomes

No objective responses in a solid-tumor phase I trial

Eight of 23 evaluable patients had stable disease, but no objective tumor responses were observed.

Safety

Peripheral neuropathy is the central concern

Numbness, tingling, pain, weakness and altered reflexes require baseline assessment and ongoing monitoring.

“
Background

What Is Dichloroacetate?

DCA is a simple chlorinated acetate compound studied for decades in lactic-acidosis and mitochondrial disorders. It inhibits pyruvate dehydrogenase kinase (PDK), which normally restrains the pyruvate dehydrogenase complex. Releasing that brake can increase the movement of pyruvate into mitochondrial oxidation.

Cancer researchers became interested because many tumors rely heavily on glycolysis even when oxygen is available—often called the Warburg effect. DCA may influence mitochondrial membrane potential, oxidative signaling and apoptosis in experimental systems.

A credible target does not guarantee a clinical benefit

Cancer metabolism is adaptable. Tumors differ in PDK expression, oxygenation, genetics and fuel use. A drug that shifts metabolism in a cell line may not control a complex human tumor by itself.

“
Clinical Research

What Human DCA Studies Have Found

Advanced solid tumors

A phase I dose-escalation study treated 24 patients. The recommended phase II dose was 6.25 mg/kg twice daily. Fatigue, neuropathy and nausea were common. No objective responses occurred; eight patients had stable disease.

Recurrent malignant brain tumors

A small open-label phase I study used genotype-informed dosing. Eight patients completed at least one cycle without a dose-limiting toxicity, while mild distal paresthesias prompted withdrawal or adjustment in two patients.

A separate five-patient glioblastoma translational report found metabolic and tissue changes consistent with target engagement, but its size and design cannot establish efficacy. Another small lung/breast study closed after seven patients because of safety concerns.

Best interpretation: DCA has enough biological and early clinical evidence to justify research interest, but not enough to be described as a proven cancer treatment.
“
Safety & Monitoring

Why Neuropathy Screening Matters

Integrative oncology physician checking hand sensation during DCA neuropathy safety monitoring
Baseline sensation, balance, reflexes and prior chemotherapy-related neuropathy should be documented before considering DCA.

DCA can inhibit its own metabolism with repeated dosing, causing blood levels and exposure to change over time. Age and GSTZ1 genetic variation may affect clearance. Peripheral neuropathy is the best-recognized clinically limiting toxicity.

  • Document existing numbness, tingling, burning pain or weakness
  • Review prior platinum, taxane, vinca or other neurotoxic therapy
  • Assess liver function and the complete medicine/supplement list
  • Recheck symptoms rather than assuming one fixed dose remains appropriate
  • Use clear pause and stop criteria if neurologic symptoms emerge
“
Combination Research

DCA May Be More Relevant as a Metabolic Partner Than a Standalone Therapy

Laboratory studies have explored DCA with chemotherapy, radiation, targeted agents and other metabolic strategies. The rationale is that altering tumor metabolism could make some cancer cells more vulnerable to another treatment. Results vary by tumor type, oxygen level, model and dose.

These preclinical combinations should not be converted directly into patient protocols. A clinically responsible plan has to account for overlapping neuropathy, liver effects, nausea, fatigue, timing and the possibility that the combination has never been tested in people.

Related reading: See our integrative treatment overview, intravenous vitamin C research and Stage 4 cancer care page.
“
Individualized Review

Questions That Matter Before Considering DCA

Cancer Context

What is the diagnosis and treatment goal?

Histology, stage, biomarkers, prior response and remaining standard or trial options frame the discussion.

Neurologic Risk

Is neuropathy already present?

Preexisting neuropathy, diabetes, nutritional deficiency and prior neurotoxic treatment may increase concern.

Evidence

Is there human evidence for this cancer?

A result in a cell line or mouse model is not interchangeable with a human response signal.

Monitoring

How will benefit and harm be measured?

Define imaging, laboratory, symptom, neurologic and oncology follow-up before treatment begins.

“
Sunridge Medical Approach

A Broader Plan, Not a Single-Molecule Promise

Patients often ask about DCA because they want a treatment that engages cancer metabolism or because previous options have been difficult. Sunridge can review that interest in the context of the whole case—without presenting early research as certainty.

  • Coordinate with current oncology care and avoid unplanned treatment delays
  • Review pathology, molecular testing and prior response
  • Screen neuropathy, medications, organ function and nutrition
  • Address quality-of-life concerns alongside disease-directed decisions
  • Reassess based on objective clinical information
Prepare for a review: Our cancer treatment resources explain records, side effects and supportive care.
“
Frequently Asked Questions

DCA and Cancer Questions

Is DCA approved by the FDA to treat cancer?

No. DCA remains investigational for cancer and is not an FDA-approved cancer treatment.

How is DCA thought to affect cancer cells?

DCA inhibits PDK, activates pyruvate dehydrogenase and can shift energy metabolism toward mitochondrial oxidation. Experimental studies also report changes in membrane potential, reactive oxygen signaling and apoptosis.

Has DCA shrunk tumors in people?

Early studies were small and mainly evaluated safety. A phase I solid-tumor study reported no objective responses, although some patients had stable disease.

What cancers have been studied?

Human reports include advanced solid tumors, glioblastoma and recurrent malignant brain tumors. Preclinical studies cover many more cancers, but preclinical activity is not proof of patient benefit.

What is the main DCA side effect?

Peripheral neuropathy is the most important dose-limiting concern. Fatigue, nausea, vomiting and diarrhea have also occurred.

Can DCA be used if I already have chemotherapy neuropathy?

That requires particular caution. Baseline symptoms, functional impact, prior agents and alternative options should be reviewed before any decision.

Does genetic testing help with DCA dosing?

GSTZ1 variation can influence DCA metabolism and has been used in research dosing approaches, but genetic testing does not establish that DCA will work against a tumor.

Can DCA be combined with chemotherapy?

Combination research is largely preclinical. Potential benefit, overlapping toxicity and timing must be considered with the oncology team rather than assumed.

Is online DCA the same as research-grade medication?

Product identity, purity, formulation and dose may differ. Purchasing an unverified product adds quality and safety risks.

Can Sunridge review whether DCA fits my case?

Yes. A consultation can examine the evidence, your current plan, neuropathy risk and whether other integrative or clinical-trial options have a stronger rationale.

“
Primary Sources & Evidence Reviews

References

  1. Chu QS, et al. Phase I Study of Dichloroacetate in Advanced Solid Tumors. Invest New Drugs. 2015.
  2. ClinicalTrials.gov. Phase I Dichloroacetate in Recurrent or Metastatic Solid Tumors.
  3. Michelakis ED, et al. Metabolic Modulation of Glioblastoma With Dichloroacetate. Sci Transl Med. 2010.
  4. Dunbar EM, et al. Phase I Trial of DCA in Adults With Recurrent Malignant Brain Tumors. Invest New Drugs. 2014.
  5. Garon EB, et al. DCA in Hypoxic Tumors and Advanced NSCLC/Breast Cancer. J Cancer Res Clin Oncol. 2014.
  6. Tataranni T, Piccoli C. DCA and Cancer: Overview Toward Clinical Applications. Oxid Med Cell Longev. 2019.
  7. Kaufmann P, et al. DCA Causes Toxic Neuropathy in MELAS: Randomized Trial. Neurology. 2006.
  8. Dichloroacetate-Induced Peripheral Neuropathy. Int Rev Neurobiol. 2019.
  9. Age-Dependent Kinetics and Metabolism of DCA: Relevance to Toxicity. J Pharmacol Exp Ther. 2008.
  10. Therapeutic Applications of DCA and the Role of GSTZ1. Pharmacol Ther. 2017.
  11. National Cancer Institute. Complementary and Alternative Medicine.
  12. National Cancer Institute. Cancer Therapy Interactions With Foods and Dietary Supplements.

This page is educational. DCA remains investigational for cancer and should not replace proven treatment or clinical-trial evaluation. Research findings may change as new studies are completed.

“
Considering a Metabolic Approach?

Start With the Cancer, the Evidence and Your Safety Profile

Our Patient Care Team can help determine which records are needed for a physician-directed review of DCA, other integrative therapies and the options still available in your case.

Request a Cancer Consultation →Call 1-800-923-7878
“
“
Living research library · positive published findings

Research organized by cancer type

Browse 2 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.

Bone cancer

Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.

2022 · Metabolism and redox biology

We synthesized a mitochondria-targeting polymer micelle (OPDEA-PDCA), in which poly[2-(N-oxide-N,N-diethylamino)ethyl methacrylate] (OPDEA) was used to target mitochondria and the conjugated dichloroacetate (DCA) was used to inhibit pyruvate dehydrogenase kinase 1 (PDHK1).

Open study on PubMed →
Sarcoma

Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.

2022 · Metabolism and redox biology

We synthesized a mitochondria-targeting polymer micelle (OPDEA-PDCA), in which poly[2-(N-oxide-N,N-diethylamino)ethyl methacrylate] (OPDEA) was used to target mitochondria and the conjugated dichloroacetate (DCA) was used to inhibit pyruvate dehydrogenase kinase 1 (PDHK1).

Open study on PubMed →

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Call Our Care Team

Toll-free: 1-800-923-7878
Local: 480-659-9135

Email

info@sunridgemedical.com

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us